UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended May 31, 2022
or
☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from [ ] to [ ]
Commission file number
LEXARIA BIOSCIENCE CORP. |
(Exact name of registrant as specified in its charter) |
Nevada |
| 20-2000871 |
State or other jurisdiction of incorporation or organization |
| (I.R.S. Employer IdentifiCAtion No.) |
|
|
|
#100 – 740 McCurdy Road, Kelowna BC Canada |
| V1X 2P7 |
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s Telephone number, including area code: 1.250.765.6424
Securities registered pursuant to Section 12(b) of the Act:
Title of Class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, Par Value $0.001 | LEXX | NASDAQ |
Warrants | LEXXW | NASDAQ |
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the last 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
Non-accelerated Filer | ☒ | Smaller reporting company | ☒ |
|
| Emerging growth company | ☐ |
If an emerging growth company, indicate by a check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Indicate the number of shares outstanding of each of the registrant’s classes of common stock as of the latest practicable date.
5,950,998 common shares as of July 13, 2022
DOCUMENTS INCORPORATED BY REFERENCE
None.
TABLE OF CONTENTS
| 3 |
| ||
|
|
|
| |
| 3 | |||
|
|
|
| |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
| 19 | ||
|
|
|
| |
| 29 | |||
|
|
|
| |
| 31 |
| ||
|
|
|
| |
| 31 | |||
|
|
|
| |
| Item 1A. |
| 31 |
| |
|
|
|
| |
| 31 | |||
| Page 2 of 33 |
PART I—FINANCIAL INFORMATION
Item 1. Financial Statements
| Page 3 of 33 |
| Table of Contents |
| Page 4 of 33 |
| Table of Contents |
| Page 5 of 33 |
| Table of Contents |
LEXARIA BIOSCIENCE CORP. | ||||||||||||||||||||||||
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY | ||||||||||||||||||||||||
(Expressed in U.S. Dollars, except number of shares) | ||||||||||||||||||||||||
|
|
|
|
|
| (Unaudited) |
|
|
|
|
|
|
| |||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||
|
|
|
| ADDITIONAL |
|
|
|
|
|
| TOTAL |
| ||||||||||||
|
| SHARE CAPITAL |
|
| PAID-IN |
|
|
|
|
|
| STOCKHOLDERS' |
| |||||||||||
|
| SHARES |
|
| AMOUNT |
|
| CAPITAL |
|
| DEFICIT |
|
| NCI |
|
| EQUITY |
| ||||||
|
|
|
|
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||||
Balance August 2020 |
|
| 3,001,476 |
|
|
| 3,001 |
|
|
| 30,324,398 |
|
|
| (27,802,198 | ) |
|
| (42,943 | ) |
|
| 2,482,258 |
|
Stock based compensation |
|
| - |
|
|
| - |
|
|
| 48,887 |
|
|
| - |
|
|
| - |
|
|
| 48,887 |
|
Net loss |
|
| - |
|
|
| - |
|
|
| - |
|
|
| (696,028 | ) |
|
| - |
|
|
| (696,028 | ) |
Non-controlling interest |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (14,093 | ) |
|
| (14,093 | ) |
Balance November 30, 2020 |
|
| 3,001,476 |
|
|
| 3,001 |
|
|
| 30,373,285 |
|
|
| (28,498,226 | ) |
|
| (57,036 | ) |
|
| 1,821,024 |
|
Stock based compensation |
|
| - |
|
|
| - |
|
|
| 17,154 |
|
|
| - |
|
|
| - |
|
|
| 17,154 |
|
Brokered placement |
|
| 2,102,856 |
|
|
| 2,104 |
|
|
| 9,469,393 |
|
|
| - |
|
|
| - |
|
|
| 9,471,497 |
|
Net Income |
|
| - |
|
|
| - |
|
|
| - |
|
|
| 404,111 |
|
|
| - |
|
|
| 404,111 |
|
Non-controlling interest |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (10,921 | ) |
|
| (10,921 | ) |
Balance February 28, 2021 |
|
| 5,104,332 |
|
|
| 5,105 |
|
|
| 39,859,832 |
|
|
| (28,094,115 | ) |
|
| (67,957 | ) |
|
| 11,702,865 |
|
Stock based compensation |
|
| - |
|
|
| - |
|
|
| 343,966 |
|
|
| - |
|
|
| - |
|
|
| 343,966 |
|
Warrants issued for services |
|
| - |
|
|
| - |
|
|
| 785,895 |
|
|
| - |
|
|
| - |
|
|
| 785,895 |
|
Net loss |
|
| - |
|
|
| - |
|
|
| - |
|
|
| (2,556,997 | ) |
|
| - |
|
|
| (2,556,997 | ) |
Non-controlling interest |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (9,555 | ) |
|
| (9,555 | ) |
Balance May 31, 2021 |
|
| 5,104,332 |
|
|
| 5,105 |
|
|
| 40,989,693 |
|
|
| (30,651,112 | ) |
|
| (77,512 | ) |
|
| 10,266,174 |
|
Exercise of warrants |
|
| 610,189 |
|
|
| 610 |
|
|
| 4,014,433 |
|
|
| - |
|
|
| - |
|
|
| 4,015,043 |
|
Shares issued for services |
|
| 12,178 |
|
|
| 12 |
|
|
| 84,988 |
|
|
| - |
|
|
| - |
|
|
| 85,000 |
|
Net loss |
|
| - |
|
|
| - |
|
|
| - |
|
|
| (1,178,092 | ) |
|
| - |
|
|
| (1,178,092 | ) |
Non-controlling interest |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (124,573 | ) |
|
| (124,573 | ) |
Balance August 31, 2021 |
|
| 5,726,699 |
|
|
| 5,727 |
|
|
| 45,089,114 |
|
|
| (31,829,204 | ) |
|
| (202,085 | ) |
|
| 13,063,552 |
|
Stock based compensation |
|
| - |
|
|
| - |
|
|
| 408,544 |
|
|
| - |
|
|
| - |
|
|
| 408,544 |
|
Net loss |
|
| - |
|
|
| - |
|
|
| - |
|
|
| (1,993,157 | ) |
|
| - |
|
|
| (1,993,157 | ) |
Non-controlling interest |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (10,325 | ) |
|
| (10,325 | ) |
Balance November 30, 2021 |
|
| 5,726,699 |
|
|
| 5,727 |
|
|
| 45,497,658 |
|
|
| (33,822,361 | ) |
|
| (212,410 | ) |
|
| 11,468,614 |
|
Shares issued for services |
|
| 224,299 |
|
|
| 224 |
|
|
| 1,199,776 |
|
|
| - |
|
|
| - |
|
|
| 1,200,000 |
|
Net loss |
|
| - |
|
|
| - |
|
|
| - |
|
|
| (1,425,777 | ) |
|
| - |
|
|
| (1,425,777 | ) |
Non-controlling interest |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (22,895 | ) |
|
| (22,895 | ) |
Balance February 28, 2022 |
|
| 5,950,998 |
|
|
| 5,951 |
|
|
| 46,697,434 |
|
|
| (35,248,138 | ) |
|
| (235,305 | ) |
|
| 11,219,942 |
|
Stock based compensation |
|
| - |
|
|
| - |
|
|
| 111,174 |
|
|
| - |
|
|
| - |
|
|
| 111,174 |
|
Net loss |
|
| - |
|
|
| - |
|
|
| - |
|
|
| (2,382,925 | ) |
|
| - |
|
|
| (2,382,925 | ) |
Non-controlling interest |
|
| - |
|
|
| - |
|
|
| - |
|
|
| - |
|
|
| (35,413 | ) |
|
| (35,413 | ) |
Balance May 31, 2022 |
|
| 5,950,998 |
|
|
| 5,951 |
|
|
| 46,808,608 |
|
|
| (37,631,063 | ) |
|
| (270,718 | ) |
|
| 8,912,778 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed consolidated interim financial statements. | ||||||||||||||||||||||||
| Page 6 of 33 |
| Table of Contents |
LEXARIA BIOSCIENCE CORP. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS May 31, 2022 (Expressed in U.S. Dollars) |
1. Nature of Business
Lexaria Bioscience Corp. (“Lexaria”, “we”, “our” or the “Company”) is a biotechnology company pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”) using our patented drug delivery technology DehydraTECHTM. Through continued validation of our research and development our focus is on national and international applications for DehydraTECH.
Revenues are primarily derived from licensing fees for the use of the Company’s patented technology to partners who pay either a fee to use DehydraTECH in the manufacturing of their own products or through the purchase of DehydraTECH manufactured products made to their specifications by Lexaria. The Company has relationships with several consumer products companies in the CBD and nutraceuticals spaces that use Lexaria’s technology in consumer goods being sold online and at retailers in the US and Canada.
The Company is headquartered in Kelowna, British Columbia, Canada. The corporate website is www.lexariabioscience.com
Going Concern Analysis
The Company’s consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and in accordance with accounting principles generally accepted in the United States (“US GAAP”) applicable to a going concern which assumes the Company will have sufficient funds to pay it operational, research and development and capital expenditures for a period of at least 12 months from the date this financial report.
Since inception, the Company has incurred significant operating and net losses. The losses attributable to common shareholders were $4.2m, $4.1m and $4.2m for the years ended August 31, 2021, 2020 and 2019, respectively. As of May 31, 2022, we had an accumulated deficit of $37.6m. We expect to continue to incur significant operational expenses and net losses in the upcoming 12 months. Our net losses may fluctuate significantly from quarter to quarter and year to year, depending on the stage and complexity of our R&D studies and related expenditures, the receipt of additional payments on the licencing of our technology, if any, and the receipt of payments under any current or future collaborations we may enter.
On January 12, 2021, the Company closed an underwritten public offering for net proceeds of $9,471,497. In the fourth quarter of the year ended August 31, 2021, the Company received $4,015,043 from the exercise of warrants.
Until the Company is able to generate significant product revenue, operations will be supported with equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We may offer additional securities for sale during fiscal year 2022 or thereafter in response to market conditions or other circumstances if we believe such a plan of financing is required to advance the Company’s business plans and is in the best interests of our stockholders. The Company has the option to raise up to one-third of its aggregate market value of its common equity held by non-affiliates through the issuance of securities pursuant to a Registration Statement on Form S-3 (333-262402) as filed with the SEC on January 28, 2022 and declared effective on February 4, 2022.
| Page 7 of 33 |
| Table of Contents |
To date, we have obtained cash and funded our operations primarily through equity financings and license agreements. In order to continue the development of our drug candidates, at some point in the future we expect to pursue one or more capital transactions, whether through the sale of equity securities, debt financing, license agreements or entry into strategic partnerships. There can be no assurance that we will be able to continue to raise additional capital in the future.
The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern. As of May 31, 2022, the Company had cash of approximately $7.0m. We believe this is sufficient to enable the Company to fund its operating and R&D expenses and any capital expenditure requirements through one year from the issuance date of these unaudited consolidated financial statements.
COVID-19
Impacts of COVID-19 Pandemic
The emergence of the COVID-19 pandemic in 2020 continues to present uncertainty and unforecastable new risks to the Company and its business plans. As of May 31, 2022, there has been no material impact on the Company’s financial position as a direct result of the pandemic. However, the Company has experienced some supply chain disruptions and shortages in the procurement of ingredients and supplies used in both our R&D activities and production. Management views this situation as transitory but cannot predict the length of time it may take for these disruptions to dissipate or if there will be a significant economic effect on the Company’s operations. In the interim, it may cause delays in carrying out our research studies and in our production schedules.
Restrictions on international travel presents a challenge in carrying out normal business activities related to corporate finance efforts and the pursuit of new customers throughout North America who might otherwise access the retail products of our licensees. As a result, the pandemic has increased the risk of lower revenues and higher losses.
During the year ended August 31, 2020, we received C$30,732 in COVID relief under the Canada Emergency Wage Subsidy programs for employees which reduced our employment costs in that year. During fiscal 2020 we also received C$40,000 from the Canadian Government sponsored Emergency Business Account loan program. As specified by the terms of this program, we repaid C$30,000 of the loan in fiscal 2021. The remaining $7,906 (C$10,000) of the loan payable is anticipated to be forgiven as directed under this program in the year ended August 31, 2023.
We continue to actively monitor the evolving effects of COVID-19 and may take further actions that alter our operations, including those that may be required by federal, state, provincial, or local authorities, or that we determine are in the best interests of our employees and third parties with which we do business.
The economic effect of the pandemic combined with increased geopolitical uncertainty and rising inflation is expected to have an impact on the Company’s future reporting periods. The effects are difficult to predict and could result in material financial impact on the Company’s financial results.
| Page 8 of 33 |
| Table of Contents |
2. Significant Accounting Policies
The significant accounting policies of the Company are consistent with those of our audited financial statements on Form 10-K for the year ended August 31, 2021.
3. Basis of Consolidation
These interim consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries; Lexaria CanPharm ULC, Lexaria CanPharm Holdings Corp., PoViva Corp., Lexaria Hemp Corp., Kelowna Management Services Corp., and Lexaria Pharmaceutical Corp., and our 83.333% owned subsidiary Lexaria Nicotine LLC (16.667% Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc.). All significant intercompany balances and transactions have been eliminated upon consolidation.
4. Basis of Presentation
The Company’s unaudited interim consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally accepted accounting principles (US GAAP) have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results for a full year or any subsequent period.
These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated annual financial statements and notes thereto included in our annual report filed on Form 10-K for the year ended August 31, 2021.
5. Estimates and Judgments
The preparation of financial statements in conformity with US GAAP requires us to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Some of the Company’s accounting policies require us to make subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. These accounting policies involve critical accounting estimates because they are particularly dependent on estimates and assumptions made by management about matters that are highly uncertain at the time the accounting estimates are made. Although we have used our best estimates based on facts and circumstances available to us at the time, different estimates reasonably could have been used. Changes in the accounting estimates used by the Company are reasonably likely to occur from time to time, which may have a material effect on the presentation of financial condition and results of operations.
The Company reviews these estimates, judgments, and assumptions periodically and reflect the effects of revisions in the period in which they are deemed to be necessary. Although we believe that these estimates are reasonable actual results could differ.
In preparing these unaudited interim consolidated financial statements, the significant judgments made by management in applying the Company’s accounting policies and the key sources of estimation uncertainty were the same as those applied to the audited consolidated financial statements for the year ended August 31, 2021.
| Page 9 of 33 |
| Table of Contents |
6. Recent Accounting Guidance
Pronouncements Issued but Not Yet Adopted
In October of 2021, the Financial Accounting Standards Board (FASB) issued an update to Government Assistance (Topic 832) to increase the transparency of government assistance and its disclosure in the notes to the financial statements. Amendments in this update take effect for annual periods beginning after December 31, 2021. Early application of the amendments is permitted. The Company does not expect the adoption of these standards to have a material impact on its consolidated financial statements
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2023. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company does not currently expect the adoption of these standards to have a material impact on its consolidated financial statements.
7. Accounts and Other Receivables
|
| May 31, |
|
| August 31, |
| ||
|
| 2022 |
|
| 2021 |
| ||
|
| $ |
|
| $ |
| ||
Trade and deposits receivable |
|
| 51,251 |
|
|
| 16,553 |
|
Sale of assets – shares receivable |
|
| - |
|
|
| 278,107 |
|
Sales tax receivable |
|
| 103,617 |
|
|
| 47,741 |
|
|
|
| 154,868 |
|
|
| 342,401 |
|
8. Inventory
|
| May 31, |
|
| August 31, |
| ||
|
| 2022 |
|
| 2021 |
| ||
|
| $ |
|
| $ |
| ||
Raw materials |
|
| 31,366 |
|
|
| 29,648 |
|
Work in progress |
|
| 8,817 |
|
|
| - |
|
|
|
| 40,183 |
|
|
| 29,648 |
|
9. Intellectual Property
Patent costs: all non-US based patent-related costs incurred in connection with preparing, filing, maintaining and prosecuting patent applications are expensed as incurred due to the uncertainty in the recovery of the expenditures. Amounts incurred are classified in general and administrative expenses.
| Page 10 of 33 |
| Table of Contents |
All related costs for US patents are recognized as Intellectual Property. When a US patent is granted, it is amortized over the remaining useful life. Any subsequent costs incurred for a US granted capitalized patent are expensed as incurred.
The following is a list of US capitalized patents held by the Company:
Issued Patent # | Patent Certificate Grant Date | Patent Family |
US 9,474,725 B1 | 10/25/2016 | Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof |
US 9,839,612 B2 | 12/12/2017 | |
US 9,972,680 B2 | 05/15/2018 | |
US 9,974,739 B2 | 05/22/2018 | |
US 10,084,044 B2 | 09/25/2018 | |
US 10,103,225 B2 | 10/16/2018 | |
US 10,381,440 | 08/13/2019 | |
US 10,374,036 | 08/06/2019 | |
US 10,756,180 | 08/25/2020 | |
US 11,311,559 | 04/26/2022 | Compositions and Methods for Enhanced Delivery of Antiviral Agents |
A continuity schedule for capitalized patents is presented below:
Patents |
|
|
|
| ||||
|
| May 31, |
|
| August 31, |
| ||
|
| 2022 |
|
| 2021 |
| ||
|
| $ |
|
| $ |
| ||
Balance – beginning |
|
| 364,623 |
|
|
| 292,000 |
|
Addition |
|
| 81,407 |
|
|
| 79,493 |
|
Amortization* |
|
| (5,355 | ) |
|
| (6,870 | ) |
Balance – ending |
|
| 440,675 |
|
|
| 364,623 |
|
*Patents are amortized over their legal life of 20 years.
| Page 11 of 33 |
| Table of Contents |
10. Property & Equipment
Nine Months Ended |
| Cost |
|
| Period Amortization |
|
| Additions |
|
| Accumulated Amortization |
|
| Net Balance May 31, 2022 |
| |||||
May 31, 2022 |
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
| |||||
Leasehold improvements |
|
| 259,981 |
|
|
| (40,528 | ) |
|
| - |
|
|
| (181,176 | ) |
|
| 78,805 |
|
Computers |
|
| 63,964 |
|
|
| (8,691 | ) |
|
| 6,817 |
|
|
| (60,241 | ) |
|
| 10,540 |
|
Furniture fixtures & equipment |
|
| 31,126 |
|
|
| (4,813 | ) |
|
| - |
|
|
| (21,233 | ) |
|
| 9,893 |
|
Lab equipment |
|
| 291,235 |
|
|
| (19,874 | ) |
|
| 42,375 |
|
|
| (89,417 | ) |
|
| 244,193 |
|
|
|
| 646,306 |
|
|
| (73,906 | ) |
|
| 49,192 |
|
|
| (352,067 | ) |
|
| 343,431 |
|
For the nine months ended May 31, 2022, amortization of $1,339 (May 31, 2021 - $9,325) was included in the cost of goods sold.
Year Ended |
| Cost |
|
| Period Amortization |
|
| Disposal |
|
| Accumulated Amortization |
|
| Net Balance August 31, 2021 |
| |||||
August 31, 2021 |
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
| |||||
Leasehold improvements |
|
| 259,981 |
|
|
| (54,038 | ) |
|
| - |
|
|
| (140,648 | ) |
|
| 119,333 |
|
Computers |
|
| 63,964 |
|
|
| (19,681 | ) |
|
| - |
|
|
| (51,550 | ) |
|
| 12,414 |
|
Furniture fixtures & equipment |
|
| 34,220 |
|
|
| (6,417 | ) |
|
| (3,094 | ) |
|
| (16,420 | ) |
|
| 14,706 |
|
Lab equipment |
|
| 291,235 |
|
|
| (35,008 | ) |
|
| - |
|
|
| (69,475 | ) |
|
| 221,760 |
|
|
|
| 649,400 |
|
|
| (115,144 | ) |
|
| (3,094 | ) |
|
| (278,093 | ) |
|
| 368,213 |
|
11. Accounts Payable and Accrued Liabilities
|
| May 31 |
|
| August 31, |
| ||
|
| 2022 |
|
| 2021 |
| ||
|
| $ |
|
| $ |
| ||
Accounts Payable |
|
|
|
|
|
| ||
Trades payable |
|
| 90,047 |
|
|
| 54,668 |
|
Sales tax payable |
|
| 47,598 |
|
|
| - |
|
Related party payable |
|
| 5,599 |
|
|
| 5,223 |
|
Accrued Liabilities |
|
|
|
|
|
|
|
|
Corporate tax payable |
|
| - |
|
|
| 1,055 |
|
Trades payable |
|
| 13,851 |
|
|
| 45,000 |
|
Balance |
|
| 157,095 |
|
|
| 105,946 |
|
12. Common Shares and Warrants
In December of 2021, the Company entered a one-year media outreach agreement to SRAX Inc. and issued 224,299 shares as consideration for an aggregate value of $1.2m of which $600,000 are included in prepaid expenses and deposits.
| Page 12 of 33 |
| Table of Contents |
During the quarter ended May 31, 2022, the Company issued no warrants. A continuity schedule for warrants is presented below:
|
| Number of Warrants |
|
| Weighted Average Exercise Price $ |
| ||
Balance August 31, 2020 |
|
| 471,608 |
|
|
| 16.77 |
|
Cancelled/expired |
|
| (44,161 | ) |
|
| 67.50 |
|
Exercised |
|
| (610,189 | ) |
|
| 6.58 |
|
Issued |
|
| 2,630,017 |
|
|
| 6.58 |
|
Balance August 31, 2021 |
|
| 2,447,275 |
|
|
| 8.00 |
|
Cancelled/expired |
|
| (25,292 | ) |
|
| 4.57 |
|
Balance May 31, 2022 |
|
| 2,421,983 |
|
|
| 8.04 |
|
A summary of warrants outstanding as of May 31, 2022, is presented below:
# of Warrants | Weighted Average Remaining Contractual Life | Weighted Average Exercise Price $ |
7,500 | 0.43 years | 24.00 |
100,000 | 1.88 years | 9.00 |
200,000 | 1.88 years | 7.00 |
51,814 | 2.46 years | 36.00 |
8,984 | 2.50 years | 36.00 |
16,667 | 2.79 years | 9.00 |
317,190 | 2.95 years | 10.50 |
1,719,828 | 3.63 years | 6.58 |
2,421,983 | 3.28 years | 8.04 |
13. Stock Options
The Company has established the Equity Incentive Plan whereby the board of directors may, from time to time, grant stock options up to the equivalent of 10% of the number of common shares issued and outstanding to directors, officers, employees, and consultants. Stock options granted must be exercised within five years from the date of grant or such lesser period as determined by the Company’s board of directors. The exercise price of an option is equal to or greater than the closing market price of the Company’s common shares on the day preceding the date of grant. The vesting terms of each grant are set by the board of directors.
During the quarter ended May 31, 2022, the Company granted 36,700 options at a strike price of $3.39 with a contractual life of 5 years. These options were awarded to employees, directors and contractors.
| Page 13 of 33 |
| Table of Contents |
A continuity schedule for stock options is presented below:
|
| Options |
|
| Weighted Average Exercise Price $ |
|
| Weighted Average Remaining Contractual Term (Years) |
|
| Aggregate Intrinsic Value $ |
| ||||
Balance August 31, 2020 |
|
| 171,604 |
|
|
| 11.17 |
|
|
|
|
|
|
| ||
Cancelled/expired |
|
| (50,334 | ) |
|
| 10.76 |
|
|
|
|
|
|
| ||
Granted |
|
| 84,900 |
|
|
| 5.41 |
|
|
|
|
|
|
| ||
Balance August 31, 2021 |
|
| 206,170 |
|
|
| 8.90 |
|
|
|
|
|
|
| ||
Cancelled |
|
| (3,334 | ) |
|
| 9.60 |
|
|
|
|
|
|
| ||
Granted |
|
| 81,800 |
|
|
| 6.23 |
|
|
|
|
|
|
| ||
|
|
| 36,700 |
|
|
| 3.39 |
|
|
|
|
|
|
| ||
Balance May 31, 2022 (Outstanding) |
|
| 321,336 |
|
|
| 6.59 |
|
|
| 3.46 |
|
|
| - |
|
Balance May 31, 2022 (Exercisable) |
|
| 293,836 |
|
|
| 6.80 |
|
|
| 3.62 |
|
|
| - |
|
The fair value of share purchase options granted were estimated as of the date of the grant by using the Black-Scholes option pricing model with the following assumptions:
|
| May 31, 2022 |
| |
Expected volatility |
|
| 98% - 119 | % |
Risk-free interest rate |
|
| 0.85% - 1.78 | % |
Expected life |
| 5 years |
| |
Dividend yield |
|
| 0 | % |
Estimated fair value per option |
| $2.50 - $5.10 |
| |
14. Revenues
Nine Months Ended | ||||||||
|
| May 31, 2022 $ |
|
| May 31, 2021 $ |
| ||
Product sales |
|
| 111,597 |
|
|
| 360,558 |
|
Licensing revenue |
|
| 16,160 |
|
|
| 326,474 |
|
Other revenue |
|
| 16,490 |
|
|
| 4,685 |
|
Income from operations |
|
| 144,247 |
|
|
| 691,717 |
|
Product revenues of $112k and licensing usage fees of $16k represent a significant decrease, year over year, in intermediate product sales and related licensing usage fees during the nine months ended May 31, 2022.
15. Segment Information
The Company’s operations involve the development and usage, including licensing, of its proprietary DehydraTECH Technology. Lexaria is centrally managed and its chief operating decision makers, being the President and the CEO, use the consolidated and other financial information supplemented by revenue information by category of alternative health consumer products and technology licensing to make operational decisions and to assess the performance of the Company. The Company has identified two reportable segments: Intellectual Property and Products. To date, licensing revenues have been significantly concentrated on one licensee.
| Page 14 of 33 |
| Table of Contents |
Nine Months Ended May 31, 2022 |
| IP Licensing $ |
|
| Products $ |
|
| Corporate $ |
|
| Consolidated Total $ |
| ||||
Revenue |
|
| 16,160 |
|
|
| 111,597 |
|
|
| 16,490 |
|
|
| 144,247 |
|
Cost of goods sold |
|
| - |
|
|
| (30,592 | ) |
|
| - |
|
|
| (30,592 | ) |
Operating expenses |
|
| (3,096,910 | ) |
|
| (430,951 | ) |
|
| (2,456,286 | ) |
|
| (5,984,147 | ) |
Segment loss |
|
| (3,080,750 | ) |
|
| (349,946 | ) |
|
| (2,439,796 | ) |
|
| (5,870,492 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets |
|
| 958,586 |
|
|
| 95,389 |
|
|
| 8,083,968 |
|
|
| 9,137,943 |
|
Nine Months Ended May 31, 2021 |
| IP Licensing $ |
|
| Products $ |
|
| Corporate $ |
|
| Consolidated Total $ |
| ||||
External revenue |
|
| 326,474 |
|
|
| 360,658 |
|
|
| 4,585 |
|
|
| 691,717 |
|
Cost of goods sold |
|
| - |
|
|
| (155,037 | ) |
|
| - |
|
|
| (155,037 | ) |
Operating expenses |
|
| 914,485 |
|
|
| (402,846 | ) |
|
| (3,909,802 | ) |
|
| (3,398,163 | ) |
Discontinued operations |
|
| (22,000 | ) |
|
| - |
|
|
| - |
|
|
| (22,000 | ) |
Segment income (loss) |
|
| 1,218,959 |
|
|
| (197,225 | ) |
|
| (3,905,217 | ) |
|
| (2,883,483 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets |
|
| 709,155 |
|
|
| 51,738 |
|
|
| 9,786,659 |
|
|
| 10,547,553 |
|
Capital Asset by Region |
| Cost US |
|
| Addition US |
|
| Net Balance US |
|
| Cost Canada |
|
| Addition Canada |
|
| Net Balance Canada |
|
| Total Net Balance |
| |||||||
Nine Months Ended May 31, 2022 |
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
| |||||||
Leasehold Improvements |
|
| - |
|
|
| - |
|
|
| - |
|
|
| 259,981 |
|
|
| - |
|
|
| 78,805 |
|
|
| 78,805 |
|
Computers |
|
| - |
|
|
| - |
|
|
| - |
|
|
| 63,964 |
|
|
| 6,817 |
|
|
| 10,540 |
|
|
| 10,540 |
|
Furniture Fixtures Equipment |
|
| - |
|
|
| - |
|
|
| - |
|
|
| 31,126 |
|
|
| - |
|
|
| 9,893 |
|
|
| 9,893 |
|
Lab Equipment |
|
| 98,050 |
|
|
| 42,375 |
|
|
| 106,506 |
|
|
| 193,185 |
|
|
| - |
|
|
| 137,686 |
|
|
| 244,193 |
|
|
|
| 98,050 |
|
|
| 42,375 |
|
|
| 106,506 |
|
|
| 548,256 |
|
|
| 6,817 |
|
|
| 236,924 |
|
|
| 343,431 |
|
Capital Asset by Region |
| Cost US |
|
| Disposal US |
|
| Net Balance US |
|
| Cost Canada |
|
| Net Balance Canada |
|
| Total Net Balance |
| ||||||
Year Ended August 31, 2021 |
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||||
Leasehold Improvements |
|
| - |
|
|
| - |
|
|
| - |
|
|
| 259,981 |
|
|
| 119,333 |
|
|
| 119,333 |
|
Computers |
|
| - |
|
|
| - |
|
|
| - |
|
|
| 63,964 |
|
|
| 12,414 |
|
|
| 12,414 |
|
Furniture Fixtures Equipment |
|
| 3,094 |
|
|
| (3,094 | ) |
|
| - |
|
|
| 31,126 |
|
|
| 14,706 |
|
|
| 14,706 |
|
Lab Equipment |
|
| 98,050 |
|
|
| - |
|
|
| 69,580 |
|
|
| 193,185 |
|
|
| 152,180 |
|
|
| 221,760 |
|
|
|
| 101,144 |
|
|
| (3,094 | ) |
|
| 69,580 |
|
|
| 548,256 |
|
|
| 298,633 |
|
|
| 368,213 |
|
16. Commitments, Significant Contracts and Contingencies
Right of Use Assets – Operating Lease
The Corporate office and R&D laboratory located in Kelowna, British Columbia, Canada is leased until November 15, 2023, with a five-year renewal option. In addition to minimum lease payments, the lease requires us to pay, subject to annual adjustments, property taxes and operating costs.
| Page 15 of 33 |
| Table of Contents |
|
| May 31, 2022 |
|
| August 31, 2021 |
| ||
|
| $ |
|
| $ |
| ||
Right of use assets – operating leases |
|
| 126,920 |
|
|
| 126,920 |
|
Amortization |
|
| (64,557 | ) |
|
| (35,879 | ) |
Total lease assets |
|
| 62,363 |
|
|
| 91,041 |
|
|
|
|
|
|
|
|
|
|
Liabilities: |
|
| 89,393 |
|
|
| 125,431 |
|
Lease payments |
|
| (33,395 | ) |
|
| (43,950 | ) |
Interest accretion |
|
| 4,166 |
|
|
| 7,912 |
|
Total lease liabilities |
|
| 60,164 |
|
|
| 89,393 |
|
|
|
|
|
|
|
|
|
|
Operating lease cost |
|
| 62,363 |
|
|
| 91,041 |
|
Operating cash flows for lease |
|
| 33,395 |
|
|
| 43,950 |
|
Remaining lease term |
| 1.4 Years |
|
| 2.1 Years |
| ||
Discount rate |
|
| 7.50 | % |
|
| 7.50 | % |
Pursuant to the terms of the Company’s lease agreements in effect, the following table summarizes the Company’s maturities of operating lease liabilities as of May 31, 2022:
2022 |
| $ | 11,204 |
|
2023 |
| $ | 44,816 |
|
2024 |
| $ | 7,469 |
|
Thereafter |
|
| - |
|
Total lease payments |
| $ | 63,489 |
|
Less: imputed interest |
|
| (3,325 | ) |
Present value of operating lease liabilities |
| $ | 60,164 |
|
Less: current obligations under leases |
|
| (41,825 | ) |
Total |
| $ | 18,339 |
|
| Page 16 of 33 |
| Table of Contents |
17. Prepaid Expenses and Deposits
Prepaid expenses consist of the following at May 31, 2022, and August 31, 2021:
|
| May 31, |
|
| August 31, |
| ||
|
| 2022 |
|
| 2021 |
| ||
|
| $ |
|
| $ |
| ||
Advertising & conferences |
|
| 684,820 |
|
|
| 168,760 |
|
Consulting |
|
| - |
|
|
| 18,750 |
|
Legal fees |
|
| 25,000 |
|
|
| 31,380 |
|
Licence, filing fees, dues |
|
| 26,250 |
|
|
| 19,500 |
|
Office & insurance |
|
| 21,238 |
|
|
| 80,863 |
|
|
|
| 757,308 |
|
|
| 319,253 |
|
18. Marketable Securities
The components of Marketable Securities were as follows:
|
| Cost Basis $ |
|
| Unrealized Gains $ |
|
| Unrealized Losses $ |
|
| Total $ |
| ||||
August 31, 2021 |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Common stock |
|
| 1,037,025 |
|
|
| 16,243 |
|
|
| (219,427 | ) |
|
|
| |
Total |
|
| 1,037,025 |
|
|
| 16,243 |
|
|
| (219,427 | ) |
|
| 833,841 |
|
May 31, 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock |
|
| 278,107 |
|
|
| 58,893 |
|
|
| (882,809 | ) |
|
| (545,809 | ) |
Total |
|
| 1,315,132 |
|
|
| 75,136 |
|
|
| (1,102,236 | ) |
|
| 288,032 |
|
Unrealized gains and losses on marketable securities are derived from Hill Street Beverage Company Inc. (“Hill Street”) (TSX-V: HILL) common stock holdings and are due, in Managements opinion, to economic uncertainties in the market sector. Management views the unrealized losses as temporary impairments based on our evaluation of available evidence.
19. Discontinued Operations
On November 19, 2020, the Company entered a definitive asset sale agreement through its wholly owned subsidiary Lexaria CanPharm ULC to sell certain non-core business assets to Hill Street for gross proceeds of C$3,850,000.
With the closing of the sale on December 10, 2020, the Company received C$350,000 in cash, 6,031,363 restricted common shares at a fair value at C$500,000 as the first required equity-based payment, and a C$2,000,000 promissory note bearing interest at 10% per annum. The promissory note was included at its nominal value of $NIL. To date, minimal interest payments have been received and are included in Other Income. Pursuant to the terms of the transaction, the Company received an additional C$1,000,000 worth of common shares of Hill Street and are included in Marketable Securities.
Gain on asset disposal |
|
|
| |
Book value of assets sold |
| $ | - |
|
Cash consideration |
|
| 273,373 |
|
Shares received |
|
| 468,264 |
|
Shares receivable |
|
| 781,067 |
|
Promissory note |
|
| - |
|
|
| $ | 1,522,704 |
|
| Page 17 of 33 |
| Table of Contents |
The financial results of the group of assets sold are presented as income (loss) from discontinued operations, net of income taxes in our consolidated statement of income. The following table presents financial results of the assets:
|
| Nine Months Ended |
| |||||
|
| May 31, |
| |||||
|
| 2022 |
|
| 2021 |
| ||
Revenue |
| $ | - |
|
| $ | 3,000 |
|
Operating Expenses |
|
| - |
|
|
| 25,000 |
|
Net Income (loss) |
| $ | - |
|
| $ | (22,000 | ) |
The following table presents cash flows of discontinued operations:
|
| Nine Months Ended |
| |||||
|
| May 31, |
| |||||
|
| 2022 |
|
| 2021 |
| ||
Cash flows used in discontinued operating activities |
|
|
|
|
|
| ||
Net income |
| $ | - |
|
| $ | (22,000 | ) |
Change in working capital |
|
| - |
|
|
| 105,000 |
|
Net cash used in discontinued operating activities |
| $ | - |
|
| $ | 83,000 |
|
|
|
|
|
|
|
|
|
|
Net cash provided by discontinued operations |
| $ | - |
|
| $ | 83,000 |
|
20. Subsequent Events
As disclosed on our Form 8-K filed on June 9, 2022, Lexaria successfully filed a pre-Investigational New Drug (“IND”) meeting request with the US Food and Drug Administration (“FDA”). The filing has been confirmed and a target date of July 30, 2022 for the meeting has been provided by the FDA, subject to certain conditions being met. The request for a pre-IND meeting formally initiates communications with the FDA regarding development of Lexaria's DehydraTECH-CBD for the treatment of hypertension. The purpose of the pre-IND meeting will be to confirm the details and acceptability of Lexaria's ongoing IND-enabling development program to be completed thereafter prior to proceeding with its full IND application filing.
As disclosed on our Form 8-K filed on June 3, 2022, the Company announced the signing of a commercial licensing agreement with Premier Wellness Science Co., Ltd. of Japan (“Premier”). Minimum quarterly payments to Lexaria will begin September 1, 2022, and, during the first five years of the Agreement, amount to US$4,527,500.
Under the terms of the Agreement, Premier is purchasing the rights to DehydraTECH technology for the Japanese non-pharmaceutical market for use with cannabidiol (“CBD”) and hemp ingredients in oral liquid and non-liquid products, as well as for topical, hair-care, lip-care and cosmetics products. Premier Wellness Science Co., Ltd. is a wholly-owned subsidiary of Premier Anti-Aging Co., Ltd. which is listed on the Tokyo Stock Exchange Mothers division with securities code 4934.
| Page 18 of 33 |
| Table of Contents |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Cautionary Note Regarding Forward-Looking Statements
This quarterly report contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained herein that are not statements of historical fact may be forward-looking statements. These statements relate to future events or our future financial performance. Any forward-looking statements are based on our present beliefs and assumptions as well as the information currently available to us. In some cases, forward-looking statements are identified by terminology such as “may”, “will”, “should”, “could”, “targets”, “goal”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks in the section entitled “Risk Factors” set forth in Item 1(A) in our annual report on Form 10-K, as filed with the Securities and Exchange Commission on November 29, 2021, that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We caution you not to place undue reliance on any forward-looking statements as they speak only as of the date on which such statements were made, and we undertake no obligation to update any forward-looking statement or to reflect the occurrence of an unanticipated event. New factors may emerge and it is not possible to predict all factors that may affect our business and prospects. Further, management cannot assess the impact of each factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
Our unaudited interim consolidated financial statements are stated in United States Dollars (“US$”) and are prepared in accordance with United States Generally Accepted Accounting Principles (“US GAAP”). The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report.
In this quarterly report, unless otherwise specified, all dollar amounts are expressed in US$. All references to “C$” refer to Canadian dollars and all references to “common shares” and “shares” refer to the common shares in our capital stock, unless otherwise indicated. The terms “Lexaria” “we”, “us”, “our” and “Company” mean the Company and/or our subsidiaries, unless otherwise indicated.
The following discussion should be read in conjunction with our condensed financial statements and accompanying notes in this quarterly report on Form 10-Q, and our audited financial statements with notes in our annual report on Form 10-K for the year ended August 31, 2021.
Overview
Lexaria’s patented DehydraTECH technology improves the delivery of bioactive compounds while promoting healthy ingestion methods, lowers overall dosing, and is highly effective in active molecule delivery available in a range of formats from oral ingestible to oral buccal/sublingual to topical products. DehydraTECH substantially improves the rapidity and quantity of Active Pharmaceutical Ingredients (“API”) transport to the blood plasma and brain using the body’s natural process for distributing fatty acids via the oral route. This technology extends across many categories beyond the primary pharmaceutical focus of the Company from foods and beverages to cosmetic products and nutraceuticals.
| Page 19 of 33 |
| Table of Contents |
Research & Development
Lexaria is advancing several R&D activities in both preclinical and clinical programs. Currently, our primary research program is the investigation of cannabidiol (CBD) for the reduction of hypertension with a human clinical trial initiated in Q3, 2022 and three human clinical trials concluded in calendar 2021. Other programs include nicotine for oral pouches and nicotine replacement therapy, antivirals and related compounds for COVID-19 and other viral diseases, PDE5 inhibitors, hormones, and others. From time to time the Company will engage in contract R&D for third parties who are interested in evaluating DehydraTECH in their products.
During the quarter ended May 31, 2022, Lexaria incurred $752,095 (May 2021- $454,443) in R&D expenditures. Specific R&D programs are in ongoing development and align to our financial ability to undertake each research phase for each API. Due to our expanding portfolio coverage, we continually examine accelerated timetable options for testing, research, and development of each API. Fiscal 2022 continues to highlight the direction of our research and development programs with confirmatory results from our ongoing programs. We continue to devote an increasing proportion of our resources and focus towards pharmaceutical applications.
This focus has led to the successful completion of a letter to request a pre-IND meeting concerning DehydraTECH CBD with the FDA and it is anticipated that the FDA shall be providing its opinions on the details and acceptability of Lexaria’s intended clinical trial program on or around July 30, 2022. Assuming the FDA’s pending pre-IND meeting feedback is fairly aligned with the proposals Lexaria put forth in its request letter, it is anticipated that Lexaria will be authorized to proceed with its initial clinical trial to enable the development of its DehydraTECH CBD, subject to the approval of a full IND application filing, in late calendar 2022 or early 2023.
CBD Studies
In September 2021 the Company reported successful results from its HYPER-H21-2 human study of DehydraTECH-CBD in arterial stiffness.
In April 2022, the Company began its multi-week human clinical hypertension study, HYPER-H21-4 for which it had received Independent Review Board approval on December 29, 2021. HYPER-H21-4 is a double blinded, randomized cross-over design study with a placebo control of 60 volunteers aged between 40-70 years. Some volunteers will already be using leading standard of care hypertension drugs such as ACE inhibitors with or without diuretics which will help evaluate the efficacy of DehydraTECH-CBD with and without other hypertension treatments. The extended duration of the study will allow Lexaria to gather critical data monitoring of DehydraTECH-CBD over time and will evaluate the potential for longer term health benefits. Further, HYPER-H21-4 should “de-risk” outcomes prior to Lexaria’s planned entry into regulatory pathways for the use of DehydraTECH-CBD to treat hypertension and possibly other forms of cardiovascular disease. Dosing for the study will be concluding in July 2022 with results to follow.
The HYPER-H21-4 study is entirely funded through the Company's existing cash resources and is not subject to any financing requirement.
In April 2022 the Company announced that all data analyses from its simulated pulmonary hypertension clinical study HYPER-H21-3 have been successfully completed with positive safety and efficacy findings. The study findings indicated a tendency (p=0.1) during 15 minutes of simulated low levels of oxygen (hypoxia) for reduced pulmonary artery systolic pressure ("PASP") with DehydraTECH-CBD treatment versus placebo. Most notably, PASP was significantly attenuated by about 5 mmHg or 41% overall (p=0.045) in male participants specifically suggesting differences by sex in responsiveness to CBD treatment under hypoxic stress conditions.
These new findings from HYPER-H21-3 will help direct prospective future research into the efficacy of DehydraTECH-CBD use for the management of elevations in pulmonary arterial pressure under hypoxic conditions (e.g., exposure to altitude), related hypoxemic pathologies (e.g., severe lung disease), and pulmonary hypertension.
| Page 20 of 33 |
| Table of Contents |
Other API Studies
In October 2021 the Company reported results from its THC-A-21-1 in vivo study of DehydraTECH-THC showing it successfully elevated THC levels in blood plasma, requiring only 15 minutes at levels comparable to those achieved in 45 minutes with concentration-matched controls.
Lexaria also published results from its NIC-A21-1 in vivo trial of DehydraTECH-NICZ (nicotine benzoate) which was delivered via oral pouches. Favorable results were all statistically significant, supporting further evaluation. Lexaria plans to progress to a larger investigation in human volunteers of DehydraTECH-nicotine versus leading brands. Lexaria is currently in the design phase of this proposed human clinical study, which will be independently funded with existing capital.
On February 2, 2022, results of our PDE5-A21-1 animal study were published by the Company which illustrated that in as little as four minutes after dosing, the DehydraTECH formulation delivered 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation. Seven minutes after dosing, the DehydraTECH-sildenafil formulation achieved an average blood level higher than the generic sildenafil control formulation reached at any point during the study.
On March 15, 2022, the Company announced that the first phase of its epilepsy research program EPIL-A21-1 has commenced. The EPIL-A21-1 research program consists of two main studies to be performed in rodents following the first phase pilot animal model. The two main studies within the program are expected to begin in May/June 2022 and will involve both an acute seizure model induced by electrical stimulation ("MES") as well as a chronic chemically induced seizure model ("RISE-SRS"). Lexaria has selected these models because they have been previously employed by other researchers studying the antiepileptic effects of CBD including select study work funded by GW with its Epidiolex® formulation (PubMed Reference Number 30588604).
The Company continues to report progress on its R&D programs through its filing of Form 8-Ks and other public releases. The results of these programs can also be found on the Company’s website: www.LexariaBioscience.com.
Patents
Our current patent portfolio includes patent family applications or grants pertaining to our method of improving bioavailability and taste, and the use of DehydraTECH as a delivery platform for a wide variety of Active Pharmaceutical Ingredients (“APIs”) including, but not limited to, fat soluble vitamins; anti-viral drugs; phosphodiesterase inhibitors; human hormones; regulated cannabinoids, and nicotine and its analogs.
We will continue to pursue patent protection in more than 40 countries around the world as vigorously as we are able, since the successful granting of more of those applications could lead to material increases in shareholder value. The Company currently has over 50 patent applications pending worldwide.
| Page 21 of 33 |
| Table of Contents |
The Company’s issued patents in the United States, Australia, Europe, India, Mexico, and Japan are as follows:
Issued Patent # | Patent Certificate Grant Date | Patent Family |
US 9,474,725 B1 | 10/25/2016 | Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof
|
US 9,839,612 B2 | 12/12/2017 | |
US 9,972,680 B2 | 05/15/2018 | |
US 9,974,739 B2 | 05/22/2018 | |
US 10,084,044 B2 | 09/25/2018 | |
US 10,103,225 B2 | 10/16/2018 | |
US 10,381,440 | 08/13/2019 | |
US 10,374,036 | 08/06/2019 | |
US 10,756,180 | 08/25/2020 | |
AU 2015274698 | 06/15/2017 | |
AU 2017203054 | 08/30/2018 | |
AU 2018202562 | 08/30/2018 | |
AU 2018202583 | 08/30/2018 | |
AU 2018202584 | 01/10/2019 | |
AU 2018220067 | 07/30/2019 | |
EP 3164141 | 11/11/2020 | |
JP 6920197 | 07/28/2021 | |
AU 2016367036 | 07/30/2019 | Methods for Formulating Orally Ingestible Compositions Comprising Lipophilic Active Agents |
JP 6963507 | 10/19/2021 | |
MX 388 203 B | 11/26/2021 | |
AU 2016367037 | 08/15/2019 | Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents |
IN 365864 | 04/30/2021 | |
JP 6917310 | 07/21/2021 | |
AU 2019256805 | 06/16/2022 | Compositions Infused with Nicotine Compounds and Methods of Use Thereof |
US 11,311,559 | 04/26/2022 | Compositions and Methods for Enhanced Delivery of Antiviral Agents |
In November of 2021, we were advised that our first patent in Mexico, in the Company’s second patent family, had been allowed.
On March 8, 2022, the Company announced it would be issued a new patent entitled "Compositions Infused with Nicotine Compounds and Methods of Use Thereof". The new Australian patent expands upon Lexaria's international intellectual property rights to apply DehydraTECH enhancement technology to most oral forms of nicotine, including pills, tablets, lozenges, capsules, pouches, gums and sprays. The patent covers many different forms of nicotine including free base nicotine, nicotine salts, polymer resins of nicotine and other forms of nicotine complexes.
On April 26, 2022 the Company was granted US Patent 11,311,559 for Compositions and Methods for Enhanced Delivery of Antiviral Agents. This is Lexaria’s 25th patent granted worldwide.
Due to the complexity of pursuing patent protection, the quantity of patent applications will vary continuously as each application advances or stalls. The Company is also filing new patent applications for new discoveries that arise from the Company’s R&D programs and, due to the inherent unpredictability of scientific discovery, it is not possible to predict if or how often such new applications might be filed.
| Page 22 of 33 |
| Table of Contents |
Reverse Stock Split
On January 11, 2021, the Company filed an amendment and restatement of its articles of incorporation to effectuate a 1-for-30 reverse stock split of the issued and outstanding shares of common stock of the Company. The purpose of the reverse stock split was to meet Nasdaq’s minimum stock price requirement. The reverse stock split did not change the number of authorized shares of common stock, which remains at 220,000,000 shares. All warrants, options, share and per share information in this Report gives retroactive effect to the 1-for-30 reverse stock split.
Public Offering
On January 14, 2021, the Company closed an underwritten public offering with the issuance of 2,102,856 shares of the Company’s common stock priced at $5.25 per share with an equivalent number of five-year warrants at an exercise price of $6.58. Additionally, 227,161 Representative Warrants were issued as partial consideration to the underwriters of the offering that have a five-year term at an exercise price of $6.58. Net of fees and disbursements, the Company received net proceeds of $9,471,497.
LEXX Market Listing
The Company’s common stock was uplisted from trading on the OTCQX under “LXRP” to the Nasdaq Capital Market where our common stock and certain of our warrants began trading under the symbols “LEXX” and “LEXXW”, respectively, effective as of the opening of market trading on January 12, 2021.
The Company, trading under the symbol “LXX”, voluntarily delisted from the Canadian Securities Exchange (“CSE”) effective after the closing of trading on Wednesday, July 7, 2021. The overwhelming majority of trading had moved to Nasdaq and by delisting from the CSE the Company expected to realize savings in fees and managerial time and effort required to maintain a dual listing.
Asset Sale
On December 9, 2020, Lexaria CanPharm ULC (“CanPharm”) completed a disposition (the “Disposition”) of its use and licensing rights to use its DehydraTECH technology (the “Assets”) specifically in association with non-pharmaceutical products containing cannabis molecules that contain 0.3% or greater THC. The purpose of the Disposition was to remove the Company’s association with cannabis as it remains a Schedule 1 Drug and thereby eliminating any such regulatory restrictions cannabis products may create. The Disposition assisted the Company in obtaining a listing on the Nasdaq Capital Market (“Nasdaq”) on January 12, 2021. As a result of the Disposition, CanPharm assigned to the purchaser, Hill Street, license agreements with three existing non-related party licensees.
In consideration for the Assets, Hill Street provided CanPharm with C$350,000 cash, a promissory note bearing a principal amount of C$2,000,000 and bearing an interest rate of 10% (the “Note”) and C$1,500,000 in shares of Hill Street, issued in three tranches over a period of 16 months from the closing date. The repayment of the Note does not have a fixed maturity date and is based on quarterly installments equal to 5% of the gross sales realized by Hill Street of DehydraTECH enabled products. Due to the uncertainty pertaining to the settlement of the Note, management concluded that the note had $Nil value at the time of the sale and was recorded as such. Some of the factors considered in the $Nil valuation of the Note were that the legal sales of THC products in the US and Canada have little or no history which made the expectant quarterly payments very difficult to forecast. Further, Hill Street had no experience selling THC products and at the time of the sale was not licensed to produce and sell such products. Therefore, the Company considered risk of default high and the collectability of the Note as highly doubtful. Since the date of sale Hill Street has repaid $5k in the year-ended August 31, 2021. We have received a further $16k in the nine months ended May 31, 2022, included in other revenues, as payment toward the accumulated interest on the Note.
| Page 23 of 33 |
| Table of Contents |
Impact of COVID-19
The COVID-19 pandemic continues to present uncertainty and unforecastable new risks to the Company and its business plan. Restrictions on national and international travel and required business closures present challenges in carrying out normal business activities related to corporate finance efforts and the pursuit of new customers throughout North America who might otherwise access the retail products of our licensees. As a result, the pandemic has increased risk of lower revenues and higher losses. To date, we have not experienced a material impact on our financial statements, impairments of any of our assets or any major business disruptions, including with our vendors.
The extent to which the COVID-19 pandemic will impact the progress of our research and development programs is subject to future developments which are highly uncertain and cannot be predicted with confidence. We continue our efforts to be proactive in managing the impact from the pandemic, including various actions to communicate with suppliers, customers, and project participants as we may deem appropriate.
We have made modifications to our normal operations including requiring team members to work remotely on a staggered basis. To the extent possible, we are conducting business as usual, with necessary or advisable modifications to employee travel. At this time, these measures will continue in force for the near term.
We will continue to actively monitor the rapidly evolving situation related to COVID-19 and may take further actions that alter our operations, including those that may be required by federal, state, provincial, or local authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business. We do not know when, or if, it will become practical to relax or eliminate some or all these measures entirely.
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.
Critical Accounting Estimates
Our consolidated financial statements and accompanying notes are prepared in accordance with US GAAP. These accounting principles require management to make certain estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses during the periods reported. These estimates, judgments and assumptions are reasonable, based on information available to management at the time that such estimates, judgments and assumptions are made. We believe that understanding the basis and nature of the estimates, judgments and assumptions involved with the following aspects of our financial statements is critical to an understanding of our financials. For a discussion of our critical accounting estimates, please read Note 2 to our financial statements in our Annual Report on Form 10-K for the year ended August 31, 2021. There have been no material changes to the critical accounting estimates previously disclosed in our Annual Report on Form 10-K for the year ended August 31, 2021.
Capital Assets
Capital assets are stated at cost less accumulated depreciation and depreciated using the straight-line method over their useful lives or otherwise by units of production.
| Page 24 of 33 |
| Table of Contents |
Intellectual Property
US patent costs, included in intellectual property, represent legal costs incurred to establish US-granted patents. These capitalized patent costs are amortized on a straight-line basis over the remaining life of the patent. When US patents reach a mature stage, any associated legal costs, including typical maintenance fees, are expensed as incurred. In the nine months ended May 31, 2022, the Company recognized $81k (May 31, 2021 - $79k) attributable to capitalized patents. All other patent costs are expensed when incurred.
Revenue Recognition
Product Revenue
Revenue from the sale of products is recognized when an arrangement exists, delivery has occurred, the sales price is fixed or determinable, and collectability is reasonably assured, which typically occurs upon shipment. The Company reports its sales net of actual sales returns.
Licensing Revenue from Intellectual Property
We recognize revenue for license fees at a point in time following the transfer of our intellectual property, our patented lipid nutrient infusion technology DehydraTECH for infusing APIs, to the licensee, which typically occurs on delivery of documentation.
Usage Fees from Intellectual Property
We recognize revenue for usage fees when usage of our DehydraTECH intellectual property occurs by licensees infusing an API into one or more of their product lines for sale.
Funding Requirements
We anticipate that our expenditures will increase in connection with our ongoing R&D program, specifically with respect to our animal and human clinical trials of our DehydraTECH formulations for the purposes of treating hypertension and infectious diseases. As we move forward with our Investigational New Drug application with the FDA, we anticipate that our expenditures will further increase and accordingly, we expect to incur increased operating losses and negative cash flows for the foreseeable future.
Through May 31, 2022, we have funded our operations primarily with proceeds from the sale of our common stock. The Company has consistently incurred recurring losses and negative cash flows from operations, including net losses of $5,870,492 and $2,883,483 for the nine months ended May 31, 2022, and 2021, respectively.
The continuation of our Company as a going concern is dependent upon our Company raising additional capital and/or attaining and maintaining profitable operations. The accompanying financial statements do not include any adjustment relating to the recovery and classification of recorded asset amounts or the amount and classification of liabilities that might be necessary should our Company discontinue operations. The recurring losses from operations and net capital deficiency do raise doubt about the Company’s ability to continue as a going concern within one year following the date that these consolidated financial statements are issued. As of the issuance date of these consolidated interim financial statements, we expect our cash and cash equivalents of approximately $7.0m as at May 31, 2022, will be sufficient to fund our operating expenses and capital expenditure requirements through the forthcoming 12 months from the issuance date of this report.
| Page 25 of 33 |
| Table of Contents |
Results of Operations for our Period Ended May 31, 2022, and 2021
Our net loss and comprehensive loss for the nine months ended and the changes between those periods for the respective items are summarized as follows:
|
| Nine Months Ended |
| |||||||||
Results of Operations |
| May 31, |
| |||||||||
|
| 2022 |
|
| 2021 |
|
| Change |
| |||
|
| $ |
|
| $ |
|
| $ |
| |||
Revenue |
|
| 144,247 |
|
|
| 691,717 |
|
|
| (547,470 | ) |
Research and development |
|
| 1,486,489 |
|
|
| 823,102 |
|
|
| 663,387 |
|
Consulting fees & salaries |
|
| 1,672,825 |
|
|
| 2,304,280 |
|
|
| (631,455 | ) |
Legal and professional |
|
| 439,942 |
|
|
| 594,158 |
|
|
| (154,216 | ) |
Other general and administrative |
|
| 2,384,893 |
|
|
| 1,199,327 |
|
|
| 1,185,566 |
|
Discontinued operations |
|
| - |
|
|
| (22,000 | ) |
|
| 22,000 |
|
Net Loss |
|
| (5,870,492 | ) |
|
| (2,861,483 | ) |
|
| (3,009,009 | ) |
Revenue
Product revenues of $112k and licensing usage fees of $16k for the period ended May 31, 2022, constitute a significant decline in intermediate product sales and related licensing usage fees. Our primary licensee experienced significant delays in the rollout of their products with a large national chain, creating a surplus of inventory from 2021 product manufactured by Lexaria. The impacts of COVID-19 including supply chain issues and the delays in legislative amendments effecting the CBD industry in the US, have left the market flat throughout 2021 and 2022.
The abilities of other licensees to generate ongoing sales, thereby increasing product and usage fees, are expected to increase in the near term as new products are developed and gain market acceptance. We have continued strong interest in our intermediate products in the US, Japan and Europe but cannot predict how long the current market conditions will affect purchasing decisions of retail customers that ultimately affect the consumer product manufacturers that utilize our intermediate products. Nor can we predict when consumer spending might show sustainable growth in the effected market sectors that could translate into substantially increased licensing or usage revenues.
Our licensing revenues consist of IP licensing fees for the transfer of the Technology and usage fees that occur over time. IP licensing fees are due at the signing of definitive agreements for the Technology and can include payments due upon transfer of the Technology and installment payments that are receivable within 12 months. Licencing revenues are expected to increase in late 2022 and early 2023 as our newly signed licensees introduce their products using our DehydraTECH technology to market.
Subsequent to the quarter ended May 31, 2022, the Company announced the granting of an exclusive licence (subject to two previously issued licenses in Japan) to Premier Wellness Science Co., Ltd. for the Japanese non-pharmaceutical market for use with CBD and hemp ingredients in oral liquid and non-liquid products, as well as for topical, haircare, lip-care and cosmetics products. In order to retain ongoing exclusivity, the negotiated minimum quarterly payments to Lexaria begin September 1, 2022, and, during the first five years of the Agreement, amount to US$4,527,500. In addition to the minimum payments, Lexaria will also receive royalty revenue from DehydraTECH licensed product sales.
| Page 26 of 33 |
| Table of Contents |
Research and Development
Expenditures on R&D increased by $633k for the period ended May 31, 2022, as the Company undertook several studies within its 2022 applied research and development program. Our primary focus in R&D has been on DehydraTECH-CBD to treat hypertension and our current study combined with our preparations for the filing of an IND (Investigative New Drug) application has contributed to a majority of the current expenditures.
Consulting Fees and Salaries
Our consulting fees decreased by $631k primarily due to non-cash stock-based compensation on options granted and vested ($728k) in the nine months ended May 31, 2021 and offset by a $99k increase in salaries in 2022 due to hiring within our R&D, investor relations and accounting departments.
Legal and Professional Fees
Our professional fees decreased by $154k during the period compared to the prior year period. The previous year’s expenditures were higher due to increased patent and trademark filings, the up-list to the Nasdaq Capital Markets, and additional advisory services utilized. We recognize certain legal fees, tax advice fees, and accounting services all as “Professional Fees.”
General and Administrative
General and administrative expenses during the nine months ended May 31, 2022, are up significantly year over year due to increased advertising ($563k) and unrealized losses increased by $737k. Otherwise expenses were generally lower. A gain on the sale of assets ($1.5m) was recognized in the nine months ended May 31, 2021.
Liquidity and Financial Condition
|
| May 31, |
|
| August 31, |
| ||
Working Capital |
| 2022 |
|
| 2021 |
| ||
|
| $ |
|
| $ |
| ||
Current assets |
|
| 8,291,474 |
|
|
| 12,442,940 |
|
Current liabilities |
|
| (206,826 | ) |
|
| (153,276 | ) |
Net Working Capital |
|
| 8,084,648 |
|
|
| 12,289,664 |
|
|
| Nine Months Ended |
| |||||
|
| May 31, |
| |||||
Cash Flows |
| 2022 |
|
| 2021 |
| ||
|
| $ |
|
| $ |
| ||
Cash flows (used in) provided by operating activities |
|
| (3,702,724 | ) |
|
| (2,877,489 | ) |
Cash flows (used in) provided by investing activities |
|
| (130,595 | ) |
|
| 193,882 |
|
Cash flows (used in) provided by financing activities |
|
| (33,395 | ) |
|
| 9,415,370 |
|
Net cash flows (used in) discontinued operations |
|
| - |
|
|
| 83,000 |
|
Increase (decrease) in cash |
|
| (3,866,714 | ) |
|
| 6,814,763 |
|
| Page 27 of 33 |
| Table of Contents |
Operating Activities
Net cash used in operating activities for the nine months ended May 31, 2022, increased by $792k for the period compared with cash used in operating during the same period in 2021. This difference was largely due to the increased expenditures pertaining to R&D and our stakeholders outreach programs.
Investing Activities
Net cash used in investing activities increased by $324k due to increased spending on capitalized US patents filings and the purchase of equipment in the nine months ended May 31, 2022, compared to 2021 which saw an inflow of cash from the sale of assets to Hill Street.
Financing Activities
Net cash provided from financing activities during the period ended May 31, 2022, is attributed to the amortized right-of-use lease payments. Cash provided by financing activities in the nine months ended May 31, 2021, of $9.4m primarily related to the underwritten public offering that closed January 21, 2021.
Liquidity and Capital Resources
We have accumulated a large deficit since inception that has primarily resulted from executing our business plan, including R&D expenditures, in seeking to identify and develop our intellectual property patents for licensing and product creation. We expect to continue to incur losses for at least the short term.
To date, we have obtained cash and funded our operations primarily through equity financings and limited amounts from revenue generation while our licensees ramp up production and market expansions. We expect to continue to evaluate various funding alternatives on an ongoing basis as needed to maintain operations, to continue our research programs and to expand our patent portfolio. If we determine it is advisable to raise additional funds, there is no assurance that adequate funding will be available to us or, if available, that such funding will be available on terms that we or our stockholders view as favorable. Market volatility and global economics may have a significant impact on the availability of funding sources and the terms at which any funding may be available.
| Page 28 of 33 |
| Table of Contents |
Short Term Liquidity
On May 31, 2022, we had $7.0m cash and $8.11m in working capital. Based on our current and upcoming research and development programs and our projected general and administration expenditures, we have determined that our cash resources are sufficient to allow us to continue operations through at least the next twelve months from the issuance date of this quarterly report.
Long Term Liquidity
It will require substantial cash to achieve our objectives for developing and patenting our intellectual property across all applicable market and industry segments. This process typically takes many years and potentially millions of dollars for each segment. If we pursue full commercial exploitation of all applicable market and industry segment opportunities, we will need to obtain significant funding from existing or new relationships, increasing revenue streams or from other sources of liquidity such as the sale of equity, issuance of debt or other transactions.
Cash requirements will vary depending on the results of our research programs and the requirements of each industry segment pursued. Pursuit of each segment will progress or be curtailed based on available sources of cash with which to execute individual segment business plans. The requirements will also be affected by transactions with existing or new relationships and the depth of regulatory requirements in each segment for compliance required to approve our IP and to market and license it. These changes to requirements and transactions may impact our liquidity as well as affect our expenditures.
Item 3. Controls and Procedures
Management’s Report on Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our President and Chief Executive Officer (Principal Executive Officer) and our Chief Financial Officer (Principal Financial and Accounting Officer) to allow for timely decisions regarding required disclosure.
As of May 31, 2022, the quarter covered by this report, we carried out an evaluation, under the supervision and with the participation of our CEO, President and CFO, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing, our CEO, President, and CFO concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of May 31, 2022.
Management’s Report on Internal Control over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting. Responsibility estimates and judgments by management are required to assess the expected benefits and related costs of control procedures. The objectives of internal control include providing management with reasonable, but not absolute, assurance that assets are safeguarded against loss from unauthorized use or disposition, and that transactions are executed in accordance with management’s authorization and recorded properly to permit the preparation of consolidated financial statements in conformity with US GAAP. Our management assessed the effectiveness of our internal control over financial reporting as of May 31, 2022. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework. Our management has concluded that, as of May 31, 2022, our internal control over financial reporting is effective in providing reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with US GAAP. Our management reviewed the results of their assessment with our Board.
| Page 29 of 33 |
| Table of Contents |
Inherent limitations on Effectiveness of Controls
Internal control over financial reporting has inherent limitations which include but is not limited to the use of independent professionals for advice and guidance, interpretation of existing and/or changing rules and principles, regulations, segregation of management duties, scale of organization, and personnel factors. Internal control over financial reporting is a process which involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human error. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements on a timely basis, however these inherent limitations are known features of the financial reporting process and it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Changes in Internal Control over Financial Reporting
During the quarter ended May 31, 2022, our controls and controls processes remained consistent with our fiscal year ended August 31, 2021. There have been no changes in our internal controls over financial reporting that occurred during the quarter ended May 31, 2022, that have materially or are reasonably likely to materially affect our internal controls over financial reporting.
Our control processes are designed to include remote workers, which we have utilized for many years. The advent of the COVID-19 pandemic has not materially impacted our internal controls over financial reporting other than increasing requirements for social distancing and some additional remote working requirements for staff.
| Page 30 of 33 |
| Table of Contents |
PART II—OTHER INFORMATION
Item 1. Legal Proceedings
We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any other material proceeding or pending litigation. There are no proceedings in which any of our directors, executive officers, or affiliates, or any registered or beneficial stockholder, is an adverse party or has a material interest adverse to our interest.
Item 1A. Risk Factors
Much of the information included in this quarterly report includes or is based upon estimates, projections or other "forward looking statements". Such forward looking statements include any projections or estimates made by us and our management in connection with our business operations. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested herein.
The risks associated with our business, common stock and other factors were with those described in the consolidated financial statements for the year ended August 31, 2021.
Item 2. Exhibits, Financial Statement Schedules
a) Financial Statements
1) Financial statements for our Company are listed in the index under Item 1 of this document
2) All financial statement schedules are omitted because they are not applicable, not material or the required information is shown in the financial statements or notes thereto.
| Page 31 of 33 |
| Table of Contents |
b) Exhibits
Exhibit Number |
| Description |
|
|
|
(3) |
| Articles of Incorporation and Bylaws |
| ||
| ||
| Amended and Restated Articles of Incorporation (Filed on Form 8-K January 14, 2021 Exh. 3.1) | |
| ||
| Amended and Restated Bylaws (Filed on Form S-1 June 3, 2020 Exh 3.4) | |
| ||
| ||
| ||
| Amendment to Articles of Incorporation – Name Change (Filed on Form 8-K May 11th, 2016 Exh 99.1) | |
|
|
|
(10) |
| Material Contracts |
| ||
| ||
| ||
|
|
|
(21) |
| Subsidiaries |
| List of Subsidiaries of the Registrant (Filed on Form 10-K November 29, 2021 Exh 21.1) | |
|
|
|
(31) |
| Rule 13(a) - 14 (a)/15(d) - 14(a) |
| Section 302 Certifications under Sarbanes-Oxley Act of 2002 of Principal Executive Officer | |
| ||
(32) |
| Section 1350 Certifications |
| Section 906 Certification under Sarbanes Oxley Act of 2002 of Principal Executive Officer | |
| ||
|
|
|
(101)* |
| Interactive Data Files |
101.INS |
| XBRL Instance Document |
101.SCH |
| XBRL Taxonomy Extension Schema Document |
101.CAL |
| XBRL Taxonomy Extension Calculation Linkbase Document |
101.DEF |
| XBRL Taxonomy Extension Definition Linkbase Document |
101.LAB |
| XBRL Taxonomy Extension Label Linkbase Document |
101.PRE |
| XBRL Taxonomy Extension Presentation Linkbase Document |
* Furnished herewith. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of any registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, and otherwise are not subject to liability under those sections.
| Page 32 of 33 |
| Table of Contents |
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
LEXARIA BIOSCIENCE CORP.
By: /s/ Christopher Bunka
Christopher Bunka
Chief Executive Officer, Chairman and Director
(Principal Executive Officer)
Date: July 14, 2022
In accordance with the Exchange Act, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
By: /s/ Christopher Bunka
Christopher Bunka
Chief Executive Officer, Chairman and Director
(Principal Executive Officer)
Date: July 14, 2022
By: /s/ John Docherty
John Docherty
President and Director
Date: July 14, 2022
By: /s/ Greg Downey
Greg Downey CPA, CMA
Chief Financial Officer
(Principal Financial and Accounting Officer)
Date: July 14, 2022
| Page 33 of 33 |
